- Home
- DGNX vs EVO Comparison
DGNX vs EVO Comparison
Compare DGNX & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGNX
- EVO
- Stock Information
- Founded
- DGNX 2018
- EVO 1993
- Country
- DGNX United Kingdom
- EVO Germany
- Employees
- DGNX N/A
- EVO N/A
- Industry
- DGNX
- EVO Biotechnology: Pharmaceutical Preparations
- Sector
- DGNX
- EVO Health Care
- Exchange
- DGNX NYSE
- EVO Nasdaq
- Market Cap
- DGNX 1.2B
- EVO 1.4B
- IPO Year
- DGNX 2025
- EVO 2021
- Fundamental
- Price
- DGNX $45.00
- EVO $3.76
- Analyst Decision
- DGNX
- EVO Buy
- Analyst Count
- DGNX 0
- EVO 2
- Target Price
- DGNX N/A
- EVO $5.90
- AVG Volume (30 Days)
- DGNX 54.9K
- EVO 159.9K
- Earning Date
- DGNX 01-01-0001
- EVO 08-13-2025
- Dividend Yield
- DGNX N/A
- EVO N/A
- EPS Growth
- DGNX N/A
- EVO N/A
- EPS
- DGNX N/A
- EVO N/A
- Revenue
- DGNX $1,177,066.00
- EVO $851,944,444.00
- Revenue This Year
- DGNX N/A
- EVO $10.08
- Revenue Next Year
- DGNX N/A
- EVO $10.99
- P/E Ratio
- DGNX N/A
- EVO N/A
- Revenue Growth
- DGNX N/A
- EVO 1.50
- 52 Week Low
- DGNX $3.60
- EVO $2.84
- 52 Week High
- DGNX $155.00
- EVO $5.64
- Technical
- Relative Strength Index (RSI)
- DGNX N/A
- EVO 41.37
- Support Level
- DGNX N/A
- EVO $4.06
- Resistance Level
- DGNX N/A
- EVO $4.44
- Average True Range (ATR)
- DGNX 0.00
- EVO 0.11
- MACD
- DGNX 0.00
- EVO -0.04
- Stochastic Oscillator
- DGNX 0.00
- EVO 0.00
About DGNX DIGINEX LIMITED
Diginex Ltd is an investment holding company. It engaged in providing Environmental, Social, and Governance (ESG) reporting solution services, advisory services, and developing customization solutions.
About EVO Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.